Drug Search Results
More Filters [+]

Muraglitazar

Alternative Names: muraglitazar, Pargluva
Latest Update: 2020-11-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: PPAR-a Agonist,PPAR-g Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Muraglitazar

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Type 2 Diabetes|Dyslipidemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CV168-062

P3

Completed

Type 2 Diabetes

2006-08-01

CV168-006

P3

Completed

Type 2 Diabetes

2006-06-01

CV168-026

P3

Completed

Type 2 Diabetes

2006-05-01

CV168-048

P3

Completed

Type 2 Diabetes

2006-03-01

Recent News Events